Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Get medical help right away
A., Wylie, P
Semaglutide Clinical Data The STEP trial program represents the most comprehensive clinical evaluation of any GLP-1 receptor agonist for weight management: STEP 1: 14.9% mean body weight loss over 68 weeks (Wilding et al., NEJM , 2021) STEP 3: 16.0% with intensive behavioral therapy over 68 weeks STEP 5: Sustained 15.2% weight loss maintained at 104 weeks with continued treatment SELECT trial: Demonstrated 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in addition to weight loss, establishing cardiovascular benefit (Lincoff et al., NEJM , 2023) The SELECT trial result is particularly significant because it demonstrated that semaglutide provides cardiovascular protection independent of weight loss, a benefit that has not been established for tesofensine
Binge Eating Disorder The safety data in this section is based on data from two 12-week parallel group, flexible-dose, placebo-controlled studies in adults with BED [see Clinical Studies 14.2]
US$ 26.84
US$ 26.85
US$ 25.01
US$ 29.06
US$ 26.72
